>> Black Swan Analysis Blog

Black Swan Analysis Blog

The need for accurate epidemiology data to drive a higher success rate with Health Technology Assessments

On September 30, 2016, Tags Director Articles

Most drug or device launches today require a health economic valuation often in the form of a Health Technology Assessment (HTA) to satisfy payers that the new ‘technology’ is advantageous for the...

Portfolio Optimisation: Can you really compare Apples to Oranges?

On July 05, 2016, Tags Director Articles

When someone uses the expression "you're comparing apples to oranges" they're really saying "Why are you trying to compare those things? You can't compare apples to oranges; they're just not the...

Forecasting In Forgotten Markets

On April 08, 2016, Tags Director Articles

Two recent healthcare events supported by the One Nucleus biotech network, has nicely highlighted some of the challenges facing healthcare companies and investors that are looking to bring...

Forecasting in Dynamic Oncology Markets

On March 14, 2016, Tags Director Articles

Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month. Firstly how exciting the market is right now, with many productive collaborations...

Shire bets big on rare diseases

On January 19, 2016, Tags Director Articles

Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases. Baxalta, the spun-off pharmaceutical...

Understanding the ‘big picture’

On July 17, 2015, Tags Director Articles

In this article, Nic Talbot-Watt, Director of Analysis and Forecasting at Black Swan Analysis, highlights the advantage of having a robust commercial understanding of their healthcare innovation...

Can rare diseases be a viable option for the pharma industry?

On October 15, 2013, Tags Director Articles

In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US...

Defining patient populations is a key trend shaping the pharma industry

On January 14, 2013, Tags Director Articles

Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the...

Enablers of drug innovation could lie in the numbers

On December 07, 2012, Tags Director Articles

Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem.

Forecasting for licensed compounds

On October 14, 2011, Tags Director Articles

Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharma forecasting.

New Call-to-action

Subscribe to Email Updates

New call-to-action
RX Brochure CTA Large

Recent Posts

Free Brochure Epiomic